As of 17 May, the Likelihood of Approval (LoA) for Shanghai Bioray Laboratory’s gene therapy BCMA-UCART for relapsed multiple myeloma (MM) dropped 12 points, according to GlobalData’s LoA data. This is the result of a delay in the study’s estimated primary completion date from November 2020 to March 2022, according to a 7 March update to

The Shanghai, China-based Bioray Laboratory’s 20-patient Phase I is a dose escalation study of intravenously infused BCMA-UCART, measuring objective response rate for up to 90 days as its primary endpoint, according to Secondary endpoints include safety and persistence of BCMA-UCART, and the study is currently recruiting at Shanghai Tongji Hospital.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

While the LoA prior to this news was 25%, GlobalData’s analysis using a combination of machine learning and a proprietary algorithm has lowered the LoA to 13%. B-cell maturation antigen (BCMA) is a multiple myeloma tumour antigen, and BCMA-UCART is an allogenic chimeric antigen receptor in T cells (CART) with potential antitumor efficacy in multiple myeloma.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.